Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329668 | 0.69 | PKM (0.55) | PKMALDH1A1PFKFB3RXFP1CCR5 | |
| SCHEMBL3686001 | 0.69 | CES1 (0.43) | PKMALDH1A1PFKFB3CCR5CAPN1 | |
| SCHEMBL6329666 | 0.67 | PKM (0.55) | PKMALDH1A1PFKFB3RXFP1CCR5 | |
| SCHEMBL3693997 | 0.66 | CCR5 (0.38) | PKMALDH1A1PFKFB3CCR5CAPN1 | |
| SCHEMBL13545247 | 0.65 | KDM4E (0.56) | PKMGHSRALDH1A1PFKFB3RXFP1 | |
| SCHEMBL13508467 | 0.65 | PPARG (0.50) | PKMALDH1A1PFKFB3CCR5 | |
| SCHEMBL13508430 | 0.65 | PPARG (0.47) | CCR5 | |
| SCHEMBL14393105 | 0.65 | PKM (0.47) | PKMGHSRALDH1A1PFKFB3CCR5 | |
| SCHEMBL14519927 | 0.64 | KDM4E (0.55) | PKMGHSRALDH1A1PFKFB3RXFP1 | |
| SCHEMBL6326184 | 0.64 | PFKFB3 (0.54) | PKMGHSRPFKFB3RXFP1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744806-B1 | NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2744806-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES | Eli Lilly and Company (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8431706-B2 | 1,2,3,4-tetrahydroqinoline derivative useful for the treatment of diabetes | ELI LILLY AND COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2013025424-A1 | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | ELI LILLY AND COMPANY (US) | 2013-02-21 | — | — | WO | disclosed |
| US-20130045990-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES | ELI LILLY AND COMPANY (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045990-A1 | NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES | SLC5A1, SLC5A2, GPR119 | PKM 3018/4885GHSR 1040/4885ALDH1A1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.